Shares of Day One Biopharmaceuticals Inc. (NASDAQ: DAWN) skyrocketed more than 65% on March 6, 2026, after the company announced a definitive agreement to be acquired by French pharmaceutical group Servier for $21.50 per share in cash, valuing the deal at approximately $2.5 billion in total equity Shareholders await confirmation of the deal's close, while the broader biotech market watches for ripple effects on similar rare-disease players. © Copyright 2026 IBTimes AU. All rights reserved. ... Plug Power Inc. (PLUG) Shares Surge More Than 23% on Strong Q4 Earnings, New CEO Appointment · Netflix Shares Hover Near $99 Amid Relief Rally After Scrapping Warner Bros. Deal · Nasdaq Composite Climbs 1.29% to 22,807 as Tech Rebound Offsets Geopolitical Jitters · Elon Musk: SpaceX IPO Buzz, Debt Repayments and AI Vision Dominate as Billionaire Navigates Busy March 2026 The buyout premium aligns with those expectations while providing certainty amid biotech sector volatility. Some investor alerts emerged post-announcement, with firms like Kahn Swick & Foti and Halper Sadeh investigating the adequacy of the price and process for shareholders. Such reviews are common in public company acquisitions but do not necessarily indicate issues. The Trade Desk Stock Surges 19% in Volatile Session on OpenAI Partnership Reports Amid Ad-Tech Recovery Hopes · Tesla Stock Dips Slightly in Early Trading Amid Robotaxi Optimism and Analyst Upgrades · Alan Greenspan Turns 100: The Former Fed Chair's Enduring Legacy as Economic Maestro Celebrates Birthday · Nasdaq Composite Closes Lower Amid Geopolitical Volatility as Iran Conflict Fuels Oil Surge and Market Swings · Intuit Shares Surge 6% on Rebound from AI Fears, Strong Fundamentals and Analyst Upgrades The company's emphasis on targeted therapies for life-threatening diseases, particularly in underserved populations, attracted Servier's interest. For investors, the deal caps a strong run for DAWN, which has delivered triple-digit year-to-date returns in 2026 amid pipeline progress and revenue growth. The stock's 52-week range spanned $5.64 to $21.23, with the acquisition pushing it to new highs.

Original title: “Day One Biopharmaceuticals (DAWN) Stock Surges 66% on Servier's $2.5 Billion Acquisition Deal”

Center for Biologics Evaluation and Research Director Vinay Prasad will exit the FDA for the second time after a controversial run that saw the oncologist butt heads with colleagues and ruffle feathers in biopharma after presiding over the rejection of several rare disease therapies.

Original title: “FDA’s Prasad To Depart FDA Following Tumultuous Term as CBER Chief”

The first week of March was a relatively brisk period for large startup funding rounds, led by three deals of $500 million or more in the space tech and AI infrastructure sectors. Stay up to date with recent funding rounds, acquisitions, and more with the Crunchbase Daily. Artificial intelligence • Health, Wellness & Biotech • Semiconductors and 5G • Startups • Venture Artificial intelligence • E-commerce • Health, Wellness & Biotech • SaaS • Startups • Venture 5. Science Corp., $230M, neurotech: Alameda, California-based Science Corp., a biotech startup focused on brain-computer interface technologies, announced it has closed on a $230 million Series C fundraise. 8. Cognito Therapeutics, $105M, neuroscience: Cambridge, Massachusetts-based Cognito Therapeutics, a developer of therapies for neurodegenerative diseases, secured $105 million in Series C funding.

Original title: “The Week’s 10 Biggest Funding Rounds: Space Tech, AI Infrastructure Lead Fundraises”

The proposed acquisition would hand Servier a couple experimental drugs in human testing as well as Ojemda, an approved therapy for certain hard-to-treat brain tumors that affect children.

Original title: “Servier to build cancer drug pipeline with $2.5B purchase of Day One”

An amylin-targeting medicine at the center of the companies’ multibillion-dollar alliance spurred less weight loss than investors had hoped, leading some analysts to question its ability to stand out.

Original title: “Roche, Zealand shares fall on ‘undifferentiated’ obesity drug results”

Servier will pick up Ojemda, which received FDA approval in 2024 to treat pediatric glioma. The drug clocked sales of $155 million for Day One Biopharmaceuticals in 2025.

Original title: “Servier Adds to Childhood Brain Tumor Portfolio With $2.5B Day One Buy”

The clearance in China comes weeks after Pfizer acquired rights to the therapy. Elsewhere, Alnylam is looking for “novel” cardiovascular targets and investors sold off Helus shares.

Original title: “Pfizer nabs first obesity approval; Alnylam, Tenaya search for heart drugs”

UniQure does not have to drill placebo burr holes in the skulls of patients with Huntington's disease, an unnamed FDA senior official said on Thursday. Instead, the company would anesthetize them and put “one to three nicks” in their scalp.

Original title: “FDA Official Fires Back at UniQure, Doubles Down on Sham-Controlled Trial”

Invea Therapeutics, a clinical-stage biotech developing oral small molecules for inflammatory diseases, withdrew its plan for an initial public offering on Friday, citing market conditions. Invea Therapeutics, a clinical-stage biotech developing oral small molecules for inflammatory diseases, withdrew its plan for an initial public offering on Friday, citing market conditions. - Renaissance Capital Invea Therapeutics, a clinical-stage biotech developing oral small molecules for inflammatory diseases, withdrew its plan for an initial public offering on Friday, citing market conditions. It had filed to raise $35 million by offering 3.2 million shares at a price range of $10 to $12.

Original title: “INAI IPO News - Inflammatory disease biotech Invea Therapeutics withdraws $35 million IPO”

STEWARTVILLE, Minn., March 5, 2026 /PRNewswire/ -- Minnesota Medical Technologies Corporation, a leading innovator in continence care solutions, today announced it has raised $20.6 million of new capital through a Series A preferred equity financing co-led by HM Venture Partners and Southeast ... About HM Venture Partners HM Venture Partners is a San Franciso-based venture capital firm that backs high growth medtech and biotech companies globally and across all stages. Founded in 2019 by Robert Luo, HMVP has three funds totaling over $600 million under management. The funds from the Series A financing will be used exclusively for: U.S. Market Entry: Establish the operation, commercial, and distribution infrastructure needed to successfully launch StaySure™ across multiple channels in the US market. Talent Acquisition: Strategically build a high-performing team across sales, marketing, and customer care to accelerate market penetration, drive market education and brand awareness, and sustainable revenue growth. With regulatory approval secured, Minnesota Medical Technologies is now positioned to scale its commercialization efforts. This Series A fundraise will allow us to accelerate physician and patient education, expand distribution channels, and support broad market penetration of this differentiated solution, unlocking meaningful value in a large, underserved global market. "This funding marks a pivotal moment for our company," said David A. Jonas, CEO of Minnesota Medical Technologies Corporation. "With the support of our investors, we are now positioned to launch StaySure™ into the newly cleared US market and expand our talented team.

Original title: “Minnesota Medical Technologies Corporation Secures $20 Million in Series A Funding to Accelerate Growth - BioSpace”

MiniMed, the diabetes business of medical device maker Medtronic , said on Thursday it has raised $560 ​million in its U.S. initial public offering. The IPO comes amid a volatile market for new listings, with companies continuing to test investor appetite despite market uncertainty stemming from the conflict in the ​Middle East and concerns over potential AI disruption. The offering valued MiniMed at $5.61 billion, based on the ⁠number of common shares outstanding listed in its IPO prospectus. Stronger IPO activity typically coincides ​with bull markets and greater investor appetite for risk.

Original title: “Medtronic's diabetes unit MiniMed raises $560 million in US IPO | Reuters”

MiniMed Group Inc., a diabetes management firm that will be separated from health-care giant Medtronic Plc, raised $560 million in a US initial public offering that priced below its marketed range.

Original title: “Medtronic Unit Raises $560 Million in US IPO Priced Below Range - Bloomberg”

The agency acted after reviewing mouse data submitted in 2024, making the timing of the new pause “confusing,” one analyst wrote.

Original title: “PepGen muscular dystrophy drug gets ‘surprise’ hold from FDA”

The alliance, which pairs Tenaya’s modality agnostic target identification and validation capabilities with Alnylam’s deep experience in RNA interference therapeutics, comes during a period of resurgence for the cardiovascular space.

Original title: “Alnylam Unites With Tenaya in Potential $1B+ Pact To Find New Genetic Heart Disease Targets”

Adam Urato, who is currently a vaccine advisor to the CDC, is closely associated with acting CDER director Tracy Beth Høeg and is a fellow skeptic of the use of selective serotonin reuptake inhibitors during pregnancy.

Original title: “FDA’s Hoeg Reportedly Trying To Hire Friend, Fellow Antidepressant Skeptic”

Nucleome has appointed Dr Michelle Morrow as CSO

Original title: “Dr Michelle Morrow”

South Korea has attracted increasing investment from the pharmaceutical industry, which is drawn to the Asian country due to its experience in antibody-drug conjugates and cell and gene therapies, according to McKinsey.

Original title: “Roche Broadens Global Clinical Trial Footprint With $480M+ South Korea Pledge”

TECregen has appointed Dr Klaas Zuideveld as CEO

Original title: “Dr Klaas Zuideveld”

Atavistik Bio is using the cash to develop “allosteric” medicines it believes can precisely impact on diseases like myelofibrosis and the blood condition HHT.

Original title: “A startup making drugs for blood disorders banks $160M”

In this episode of Denatured, you'll listen to Ram May-Ron, managing partner at FreeMind Group, and Ravi Kiron, managing director at Biopharma Strategy Advisors. We'll be speaking about how to combine nondilutive funding and family office money into a unified strategy that gets companies through the drug development valley of death.

Original title: “From Grants to Family Offices: Building a Unified Financing Strategy in Biotech”